智通财经APP讯，堃博医疗-B(02216)发布公告，本公司的肺部影像处理软件 BroncQCT® (下称“本软件”)正式获得浙江省药品监督管理局批准于中国上市。本软件获准上市反映本集团一直致力于开发提升临床获益的解决方案，并进一步巩固本公司于肺部疾病精准介入诊断及治疗领域的地位。预计本软件能够提升医生对肺部电脑断层扫描(CT)影像的阅片效率，为临床辅助诊疗提供强大助力，推动诊断过程更加高效及精准。
本软件通过算法对CT影像进行处理，进行肺部的肺段分割与分析，实现量化数据可视化以及肺部结构的三维重建，为专业医生提供阅片报告，跨越多种应用，临床价值显著。本软件可用于在患者群体中高效进行大范围影像筛查，识别具有特定肺部特征的患者。此外，本软件支持对同一个患者的不同时期的影像进行分析，允许客观比较及监控肺部参数随时间的变化，从而优化临床工作流程的效率。联合公司介入治疗产品InterVapor®热蒸汽治疗系统及BroncAblate®智衡®射频消融系统，提供肺部疾病筛查-诊断-治疗全流程的解决方案，全方位守护患者肺部健康。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.